Search results
Showing 76 to 90 of 174 results for leukaemia
Avapritinib for treating advanced systemic mastocytosis (TA1012)
Evidence-based recommendations on avapritinib (Ayvakyt) for treating advanced systemic mastocytosis in adults.
Find out which guidance and quality standards are awaiting development
New take at home drug recommended for people with chronic lymphocytic leukaemia
Our latest draft guidance recommends pirtobrutinib, a new take at home tablet, that could give patients greater choice and reduce the need for frequent hospital visits.
New take at home drug recommended for people with chronic lymphocytic leukaemia Our latest draft guidance recommends pirtobrutinib, a...
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Awaiting development Reference number: GID-TA11087 Expected publication date: TBC
View a complete list of all our guidance, NICE advice and quality standards currently in development
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
See a complete list of all our guidance and quality standards currently open for consultation
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.
Past technology appraisal appeals and decisions
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
New take at home drug recommended for people with chronic lymphocytic leukaemia Our latest draft guidance recommends pirtobrutinib, a...
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Discontinued Reference number: GID-TA10767
Awaiting development Reference number: GID-TA11748 Expected publication date: TBC